Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease

Idiopathic multicentric Castleman disease (iMCD) is a rare condition. The pathogenesis is incompletely understood; however, interleukin-6 (IL-6) is a major mediator. The clinical presentation is heterogeneous, from mild constitutional symptoms to severe multi-organ failure. The diagnosis is challenging, as it incorporates clinicopathologic criteria and requires careful evaluation to exclude various systemic disorders. Targeting IL-6 activity forms the cornerstone of modern therapy for iMCD, with siltuximab recommended as first-line therapy. Rituximab-based regimens are recommended for second-line therapy. However, many patients do not achieve adequate responses with limited evidence to guide further therapy. In the context of these substantial challenges, herein we provide a multidisciplinary Australasian clinical practice guideline to characterise clinical and pathological features, summarise treatment pathways and discuss clinical outcomes of the condition. The objective is to develop a multidisciplinary clinical practice guideline in the diagnosis and management of iMCD in Australia.

Authors

Institutions

Publication Details

Journal
Internal Medicine Journal
Published
2026-05-30
DOI
https://doi.org/10.1111/imj.70460
Primary Topic
Viral-associated cancers and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease

Jun Yen Ng, Dipti Talaulikar, Hugh C. Caterson, Jacinta Perram et al.
Internal Medicine Journal
Viral-associated cancers and disorders
article

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease

Jun Yen Ng, Dipti Talaulikar, Hugh C. Caterson, Jacinta Perram, Dejan Radeski, Maureen Rischmueller, Connull Leslie, Adam Bryant, Nicholas Weber, Pravin Hissaria, H Miles Prince, Stephen Lade, Pratyush Giri, Annmarie Bosco, Craig Wallington‐Gates, Alberta Hoi, Simon J. Harrison
article en

Abstract

Idiopathic multicentric Castleman disease (iMCD) is a rare condition. The pathogenesis is incompletely understood; however, interleukin-6 (IL-6) is a major mediator. The clinical presentation is heterogeneous, from mild constitutional symptoms to severe multi-organ failure. The diagnosis is challenging, as it incorporates clinicopathologic criteria and requires careful evaluation to exclude various systemic disorders. Targeting IL-6 activity forms the cornerstone of modern therapy for iMCD, with siltuximab recommended as first-line therapy. Rituximab-based regimens are recommended for second-line therapy. However, many patients do not achieve adequate responses with limited evidence to guide further therapy. In the context of these substantial challenges, herein we provide a multidisciplinary Australasian clinical practice guideline to characterise clinical and pathological features, summarise treatment pathways and discuss clinical outcomes of the condition. The objective is to develop a multidisciplinary clinical practice guideline in the diagnosis and management of iMCD in Australia.

Internal Medicine Journal
Australian National University (AU), Royal Adelaide Hospital (AU), The University of Melbourne (AU), Royal Brisbane and Women's Hospital (AU), Epworth Hospital (AU), UCL Australia (AU), Peter MacCallum Cancer Centre (AU), Liverpool Hospital (AU), Sir Charles Gairdner Hospital (AU), Canberra Hospital (AU), UNSW Sydney (AU), Queen Elizabeth Hospital (AU), St Vincent’s Private Hospital Sydney (AU), Sunshine Coast University Hospital (AU), Prince of Wales Hospital (AU), Monash Health (AU), Pathwest Laboratory Medicine (AU), ACT Government (AU), The University of Adelaide (AU), Neuroscience Research Australia (AU)
Openalex Percentile: Top 6%
Viral-associated cancers and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.